Two congressmen have asked Food and Drug Administration Commissioner Margaret Hamburg to answer questions about the agency's handling of the investigation into the source of contaminated heparin linked to more than 200 deaths in 2008.
Lawmakers seek to question Hamburg about heparin probe
In a letter sent to Hamburg, U.S. Reps. Joe Barton (R-Texas), ranking member on the House Energy and Commerce Committee, and Michael Burgess (R-Texas), ranking member of the panel's Oversight and Investigations subcommittee, said the FDA has failed to follow up on leads linking Chongqing Imperial and other Chinese drug suppliers to multiple lots of contaminated heparin identified during the 2008 recalls.
“We are very troubled by how FDA has handled the investigation to find out who was responsible for the contaminated heparin,” wrote Barton and Burgess. “The staff has learned that FDA has specific and credible information about certain Chinese heparin firms that warrants further investigation as suspect entities responsible for contaminating the heparin supply.”
Barton and Burgess have asked Hamburg to provide details about the agency's strategy regarding the unresolved investigation, as well as information about what actions the FDA plans to take should it identify manufacturers responsible for producing the contaminated blood thinner.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.